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A b s t r a c t
Myocardial infarction (MI) is most commonly caused by atherosclerosis and/or inflammatory processes of coronary artery walls.
The consequence of those phenomena is instability of the atherosclerotic plaque, activation of the coagulation cascade and throm-
bus formation which occludes the lumen of the vessel. Vasospasm and microembolisation may participate in MI pathogenesis. In young
individuals with diagnosis of MI, coronarography often reveals no pathologies. Is reported that MIs without significant changes of the
coronary arteries occur in 1% to 12% of patients. In this article we focus on chemical substances, medicines among them, which can
be a cause of MI.
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Special paper
Myocardial infarction in the course 
of seminoma chemotherapy
We describe the case of a 39-year-old man, with no pre-
vious history of ischemic heart disease and no cardiovas-
cular risk factors. The patient was admitted to the clinic
because of ST segment elevation myocardial infarction
(STEMI) of the antero-lateral wall, which occurred during the
cycle of chemotherapy of seminoma. Six weeks before, after
diagnosing testicle neoplasm with metastases dissemina-
tion to retroperitoneal and supraclavicular lymph-nodes
(T2N2M1S2 – degree of advancement IIIa), orchiectomy was
performed and the patient was qualified for chemothera-
py with bleomycin (0.4 U/kg), etoposide (100 mg/m2) and
cisplatin (20 mg/m2) (BEP). A week after the first cycle of
BEP stenocardial chest pain occurred, which remained on
admission to the cath lab. In ECG there was ST-segment 
elevation in antero-lateral leads. The patient was given
aspirin (300 mg p.o.), clopidogrel (600 mg p.o.) and unfrac-
tionated heparin (5000 U i.v.). In coronarography there was
an irregular, ulcerated, boundary atherosclerotic plaque found
in the proximal part of the left anterior descending artery.
The plaque was not significant, with haziness which may cor-
 respond to thrombus (Figure 1) with TIMI 3 flow [1, 2].
During coronarography chest pain resolved and ECG
recording normalized. Because of the overall clinical picture,
two-antiplatelet therapy was maintained and low molecu-
lar weight heparin was included (enoxaparin 2 × 80 mg/day
s.c.) for 7 days. The coronarography performed after a week
showed a normal picture of coronary arteries (Figure 2).
In echocardiography hypokinesis of the apex and basal
segment of the antero-septal wall with ejection fraction of
65% was found. The patient was discharged with the rec-
ommendation of regular taking of aspirin, clopidogrel, 
β-blocker, angiotensin receptor blocker and statin, and direct-
ed to further chemotherapy. At present the patient has
undergone three cycles of BEP, feels good and there is no
presence of cancer cells in PET. 
The BEP scheme used for the treatment of seminoma
is approved in treatment of testicular tumors derived from
germ cells. Cisplatin and etoposide in this protocol are admin-
istered for 5 days in cycles every 21 days, the number of
cycles varying from 2 to 4. Bleomycin is administered on
days 1, 8 and 15 of therapy. High effectiveness of BEP is ac -
companied by serious sides effects such as pulmonary fibro-
sis, neutropenia and neurotoxicity.
Medicines and chemical substances that
can cause myocardial infarction
Some drugs and chemical substances can cause MI, and
their mechanisms can be diametrically different: from a di -
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rect toxic effect on cardiomyocytes to probably the most com-
mon mechanism, which is vasospasm. There are cases of
MI caused by chemotherapeutics [3], antimigraine drugs (trip-
tans) [4], antibiotics (amoxycillin with clavulanic acid,
cefuroxime) [5, 6] bromocriptine, β-blockers, pseudoephedrine
(common supplement of antitussive medications) [7],
acetylsalicylic acid (ASA), steroidal and non-steroidal anti-
inflammatory drugs [8], allopurinol, drugs inhibiting appe-
tite and tyrosine. Also documented is the risk of MI after
ingestion of such substances as ecstasy, methamphetamine,
LSD, cocaine, heroin [7] and volatile substances (propane-
bu tane) [9]. 
Mechanisms of drug cardiotoxicity 
and other chemical substances 
Anti-cancer drugs: cisplatin and 5-fluorouracil
At greater risk of developing cardiovascular complica-
tions during treatment with cisplatin and 5-fluorouracil 
(5-FU) are patients with a history of ischemic heart disease
and numerous cardiovascular risk factors. Harmfulness of
those drugs comes from the effects they cause at systemic,
tissue, cellular and mitochondrial levels [10]. Harmful
effects of drugs can result from direct action on membrane
receptors, second messenger system, channels and ion
pumps and also on intracellular organelles [11]. By an action
of modifying the morphology of ion channels drugs can influ-
ence polarization and depolarization of cardiomyocytes, lead-
ing to arrhythmias or impairment of left ventricular systolic
and diastolic function. It points to drug interaction with
potassium channel h-ERG in cardiomyocytes. Drugs from
the antidepressant tricyclic group inhibit this channel indi-
rectly, contributing to the prolongation of QT interval and
increased risk of malignant arrhythmia [11, 12]. Also endo -
thelial damage caused by chemotherapeutics is known as
a risk factor for myocardial infarction [13]. In the case of cis-
platin different pathomechanisms can lead to MI. This alky-
lating cytostatic activates platelet aggregation, raises the
production of thromboxane and activates the arachidon-
ic acid pathway [14]. It also increases the synthesis of tumor
necrotizing factor (TNF). As a result of tubular damage, cis-
platin can cause hypomagnesemia, which sensitizes the ves-
sels to noradrenaline, acetylcholine, serotonin, angiotensin,
and potassium, and thus can cause spasm of the arteries
[10]. During the treatment with 5-FU clinical symptoms of
cardiotoxicity (ischemic changes in ECG, chest pain, MI, sud-
den cardiac death) occurred, ac cording to data from ret-
rospective studies, in from 1.6% to 10.2% of patients [15].
In a prospective study, Rezkalla et al. showed changes in
the ST segment (elevations and depressions more than 
1 mm) in 68% of patients who underwent intravenous infu-
sion of 5-FU. In those patients ische mic changes were asymp-
tomatic but after the end of infusion two sudden deaths
were recorded in the 25-patient study group [16]. Anoth-
er study showed that the treatment with 5-FU and cisplatin
was associated with occurrence of supraventricular arrhyth-
mias (53%), ventricular arrhythmias (47%), and in 31% of
patients ST segment deviation such as elevation and depres-
sion was observed [17]. According to the dose and the dura-
Fig. 1. Atherosclerotic plaque in left anterior descend-
ing artery
Fig. 2. Control coronary angiography
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tion of treatment subsequent ECG findings are observed:
ST-segment elevation, negative T wave in precordial leads
and high pointed T wave. Overall mortality in the course
of 5-FU treatment was assessed in different studies from
2.2% to 13%, and a higher incidence of complications 
correlated with higher dose of the drug (> 800 mg/m2) 
and continuous infusion compared to boluses. Complica-
tions most commonly occurred in 2 to 5 days after 5-FU infu-
sion [14].
5-Fluorouracil impairs the body's antioxidant defense
at the cellular level, thus intensifying lipid peroxidation and
subsequent damage to the endothelium. It also negatively
interferes with the production of nitric oxide [18]. In addi-
tion, it leads to DNA damage, blocking of ATP and release
of proapoptotic proteins. Experimental studies showed that
5-FU causes dose-dependent and time-dependent deple-
tion of high-energetic phosphates and citrate accumula-
tion in the myocardium [19]. In pathogenesis of acute
ischemia of myocardium disorders of coagulation and fib-
rinolysis can be involved [20]. During 5-FU therapy an in -
crease in fibrinopeptide A (FPA) and a decrease in tissue plas-
minogen activator (t-PA) were observed [21]. 5-Fluorouracil
can also cause a coronary artery spasm. Reference is made
here to impairment of nitric oxide synthase as well as
endothelium-independent vasoconstriction mediated by 
protein kinase C. The coronary artery spasm may also occur
under the influence of a pro-drug of 5-FU – capecitabine.
Particularly exposed to the risk of such complications
are patients with coronary heart disease in their history.
Such a relationship may be due to the expression of thymi-
dine phosphorylase in atherosclerotic plaques; this enzyme,
present in high doses within the tumor, is responsible for
conversion of 5’-deoxy-5-fluorouridine (5’-DFUR) (capeci -
tabine metabolite) to 5-FU [19, 22].
Non-steroidal anti-inflammatory drugs
Cardiovascular complications in use of non-steroidal anti-
inflammatory drugs (NSAIDs) are mostly due to endothe-
lial cell damage [23]. It is a well-known adverse effect of
selective inhibitors of cyclo-oxygenase-2 (COX-2) such as
rofecoxib, which caused a five-fold rise of cardiovascular
risk [24]. Efficiency of coxibs in inflammatory disease treat-
ment is comparable to NSAIDs but with reduced side-effects
from the gastrointestinal tract. However, because of the sig-
nificant increase of cardiovascular risk in patients treated
with rofecoxib, it was withdrawn from the market. Adverse
effects could be precisely due to selective COX-2 inhibition.
Cyclooxygenase-2 is mostly responsible for development
of inflammation. After in vitro research it was suggested
that laminar shear stress in endothelial cells causes ex pres-
sion of COX-2, which becomes a source of anti-aggregative
prostaglandin I2 (PGI2) [24, 25]. Furthermore, COX-2 inhi-
bition may activate the lipoxygenase pathway and conse-
quently intensify production of leukotrienes, stimulating
coronary vasospasm. Due to weaker inhibition of COX-2 rel-
ative to COX-1, celecoxib as a less selective inhibitor of COX-
2 should be safer compared to selective coxibs. It is still used
in treatment of inflammation and pain, in rheumatic dis-
orders and in patients with familial adenomatous polypo-
sis. Nevertheless, in some studies in patients treated with
celecoxib, a dose-dependent increase of cardiovascular risk
(including myocardial infarction) was revealed [26]. To sum
up, unfavorable effects of NSAIDs, both non-selective and
selective for COX-2, are multipoint; therefore it is difficult
to indicate the most significant mechanism. It appears that
their influence on endothelium is crucial.
Antiretroviral therapy
Despite the efficiency of combined antiretroviral ther-
apy in HIV-positive patients, many side-effects are observed.
It was proven, in the multicenter prospective study of the
DAD workgroup, that Highly Active Antiretroviral Therapy
(HAART) caused increase of MI risk by about 26% per year
of HAART. Age, smoking status (currently or in the past),
history of cardiovascular diseases and male sex are inde-
pendent risk factors in these patients [27]. The mechanism
of action at cell level during HAART is due to the rising con-
centration of reactive oxygen species (ROS). These parti-
cles are side-products of metabolic reactions which occur
in mitochondria. Intracellular level of ROS higher than antiox-
idative abilities of the cell causes damage of macromole-
cules such as lipids, proteins and DNA. Cardiomyocyte apop-
tosis caused by zidovudine is initiated by caspase-3 and -7
and ADP-ribose polymerase concentrations, and also de -
pends on the concentration of mitochondrial ROS [28]. In
HIV-positive patients treated with abacavir myocardial infarc-
tion risk is rising [29]. Among nucleoside reverse transcriptase
inhibitors (NRTI) abacavir, and in a lower degree didano-
sine, increase incidence of MI among patients currently treat-
ed with them and also a few months after the drug’s ces-
sation. In other drugs in the same pharmacological group
there were no similar observations (neither stavudine nor
zidovudine). A significant rise of MI incidence among HIV-
positive patients was observed after introduction of pro-
tease inhibitor (PI) on the market, and also treatment with
PI was an independent risk factor of MI [30]. During ther-
apy with PI development of lipodystrophy, hyperlipidemia,
hyperglycemia and insulin resistance is possible even in 60%
of patients. These processes undoubtedly increase car-
diovascular risk [31]. Binding of PI with LDL-related protein
(LRP) impairs chylomicron uptake in the liver and endothe-
lial triglyceride clearance, leading to hyperlipidemia and
insulin resistance [32]. HIV infection could cause many unfa-
vorable changes in the cardiovascular system, e.g. vasculitis
(polyarteritis nodosa, Henoch-Schönlein purpura), drug-
induced hypersensitivity vasculitis [33], Takayasu’s disease
[34], and Kawasaki’s disease-like syndrome [35]. Unfavor-
able effects of HIV infection on the cardiovascular system
are presumably due to damage and dysfunction of endo -
thelium [36], and also action of HIV-infected macrophages
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stimulating leukocyte adhesion or intensifying arteritis, and
in this way increasing atherosclerosis progression. Coronary
arteries are damaged by activation of cytokines, adhesive
molecules and also changes in class I major histocom-
patibility complex on the surface of the smooth-muscle cell
[32]. It is not inconceivable that viral glycoprotein gp120
induces apoptosis of the smooth-muscle cells [37]. Abnor-
mality in coagulation (increased concentrations of D-di mer,
plasminogen activator inhibitor-1, tissue plasminogen
activator antigen) was also observed [31].
Drugs
Complications due to drugs and other psychoactive sub-
stances are still an increasing problem. It is proven that 41%
of American adolescents are marihuana smokers, 13% of
teenagers use ecstasy, 11% methamphetamine, 10% LSD,
9% cocaine and 4% heroin [7]. Cocaine users in Europe are
estimated at 12 million people [38]. Mechanisms which lead
to cardiac complications after cocaine, amphetamine or
ecstasy use are: vessel damage, prothrombotic effect and
direct myocardial injury [39]. Furthermore, increase of oxy-
gen consumption as a consequence of higher blood pres-
sure and heart rate in a situation of simultaneous coronary
artery spasm may lead to acute ischemia of cardiac mus-
cle. As in the case of above-described medication groups,
endothelial dysfunction (increase of endothelin-1 produc-
tion, reduction of expression and production of nitric
oxide synthase) and also prolonged vasospasm cause
ischemia and can lead to MI. Risk of acute coronary syn-
drome is 24-fold higher in a drug user within the 1st h after
use than in people who are not on drugs.
Carbon monoxide
Carbon monoxide poisoning is one of the most com-
mon causes of hospitalization on ER departments in
western countries. Clinical symptoms and the course of poi-
soning poorly correlate with the serum level of carboxy-
hemoglobin. The most common symptoms are: cardio -
toxicity, such as malignant arrhythmias, ECG ischemic
changes and MI. Also there was observed rapid pulmo nary
edema [40]. The mechanism leading to such drastic com-
plications is higher affinity to hemoglobin molecules than
CO molecules. Consequently, there is an exchange of oxy-
gen molecules of the compounds of O2-Hg. The resulting
carboxyhemoglobin is ineffective when it comes to the de-
livery of oxygen to tissues and leads to ischemia [41]. Mech-
anisms mentioned in the literature that may be a cause of
a heart attack due to exposure to CO include: the block-
ing of the main bonds of hemoglobin, which is an oxygen
carrier, toxic effects on the mitochondria by the formation
of a ligand of cytochrome a, a3-CO, which paralyzes the so-
called mechanisms of cellular respiration, and eventually
CO may cause thrombus formation in the coronary arter-
ies, both in patients with atherosclerosis and in those with-
out atherosclerosis [42]. In in vitro studies in mice, Stein 
et al. demonstrated the cytoprotective effect and the anti-
apoptotic effect of CO molecules on the myocardium. By
the utilization donor molecule CO-CORM-3, in the mouse
organism there is observed a late defense reaction against
MI. It involves a cascade of transcription including factors
nuclear factor κB (NF-κB), STAT1/3 and Nrf2 with subsequent
increase of cardio-protective and anti-apoptotic sub-
stances in myocardium [43].
Appetite suppressants
Among medications which inhibit the hunger center [44]
unfavorable effects were observed in treatment with phen-
termine and sibutramine. Phentermine works on the hypo-
thalamus to stimulate adrenal glands to release norepi-
nephrine, a chemical messenger that signals the fight-or-flight
response and reduces hunger. Sibutramine is a centrally act-
ing serotonin-norepinephrine reuptake inhibitor. Side-effects
of these medications are strongly expressed and related to
excessive sympathetic activation. They include increase of
heart rate, myocardial contractility, conduction and also a vaso-
constrictive effect [45]. Increased incidence of MI and stroke
was observed among patients treated with these appetite
suppressants. Phentermine is not registered in Poland and
sibutramine has been withdrawn from the market.
Spasm of coronary artery
One of the causes of acute coronary syndrome and
arrhythmias in young people can be a coronary artery spasm
[7]. As mentioned above, the frequency of myocardial infarc-
tion in patients with a normal coronary artery is assessed
at 1–12% and in the group of patients at age below 35 years
the rate reaches 20%. In this population, in teenagers and
young adults, there is observed an increasing number of
MIs induced by stimulants and narcotics. The most fre-
quently used are alcohol, marijuana, nicotine and cocaine.
These substances exaggerate endothelial dysfunc-
tion, intensify platelet aggregation and sympathetic activ-
ity, and cause reduction of nitric oxide (NO) synthase activ-
ity in the vascular wall. A low level of basic nitric oxide
secretion due to impairment of endothelial function and in -
creased contractility due to higher kinase Rho/Rho activ-
ity are mentioned as the most important causes inducing
vasospasm.
Among other factors predisposing to vasospasm are:
increased sympathetic activity, oxidative stress, chronic
inflammation and hypomagnesemia. Other factors which
can lead to spasm of the coronary artery are genetic fac-
tors such as polymorphism of the gene responsible for syn-
thesis of nitric oxygen synthase and synthesis of paraox-
onase [46].
Another mechanism of spasm was described in the
course of Kounis syndrome [47]. Kounis syndrome is a ge -
neralized allergic reaction, which can be triggered by me -
dication and leads to degranulation of mast cells. These mast
cells are localized in adventitia of coronary arteries and near
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the plaque. Kounis syndrome, characterized by sudden
release of inflammatory markers such as histamine and pro-
teolytic enzymes (chymase, tryptase), causes lysis of col-
lagen covering the plaque. These reactions lead to throm-
bogenic material exposure and to activation factors of the
coagulation cascade. Moreover, into the circulatory system
are released other substances, such as products of arachi-
donic acid metabolism, cytokines, chemokines and platelet
activating factor (PAF) [47–49]. Drugs which can induce Kou-
nis syndrome are: antibiotics (ampicillin, amoxicillin,
cefuroxime, penicillin, sulbactam, vancomycin), steroids
(betamethasone, hydrocortisone), chemotherapeutics (5-
FU, sirolimus, paclitaxel), analgesics (etomidate, suxam-
ethonium), non-steroidal anti-inflammatory drugs (acetyl-
salicylic acid, ibuprofen, metamizole), anticoagulants and
fibrinolytics (heparin, streptokinase, urokinase). There
were described symptoms of Kounis syndrome after use
of allopurinol, enalapril, esmolol, omeprazole and contrast
medium as well. Such complications were also observed as
a reaction to a stent component (nickel) and drug-eluting
stent (paclitaxel) [33, 34].
Conclusions
In patients without symptoms before the planned
chemotherapy it is particularly important to assess the pro-
file of coronary disease risk factors for prevention of heart
attack. Higher cardiovascular risk of complications occurs
among patients with a history of anaphylaxis. In patients
with normal coronary arteries and history of heart infarc-
tion, due to a common cause of coronary instability which
is coronary artery spasm, it is advisable to consider a test
with ergonovine or acetylcholine. In such patients, the first
choice treatment is the use of calcium channel blockers and
nitrates. Another issue is the need for education, especial-
ly of young people, about the dangers of the use of drugs,
including the possibility of causing a heart attack.
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